慢性阻塞性肺疾病患者流感疫苗和23价肺炎球菌多糖疫苗接种现状及影响因素分析

doi:10.12183/j.scjpm.2026.0973

Abstract

CLC Number:

R186

Han Qianqian, Hu Wenhui, Wei Lifang, et al. Uptake of influenza and 23-valent pneumococcal polysaccharide vaccines and associated factors among patients with chronic obstructive pulmonary disease[J].South China Journal of Preventive Medicine, 2026, 52(8): 973-977.

References

[1] Calverley PMA, Walker PP.Contemporary Concise Review 2022: Chronic obstructive pulmonary disease[J]. Respirology, 2023, 28(5): 428-436.
[2] Al Wachami N, Guennouni M, Iderdar Y, et al.Estimating the global prevalence of chronic obstructive pulmonary disease (COPD): A systematic review and meta-analysis[J]. BMC Public Health, 2024, 24(1): 297.
[3] Li Y, Zhang P, An Z, et al.Impact of influenza and pneumococcal polysaccharide vaccination on economic burden from acute exacerbations of chronic obstructive pulmonary disease - Hebei Province, China, November 2018 to November 2020[J]. China CDC Wkly, 2023, 5(20): 452-458.
[4] 戴晓瑛, 周溪, 符之月. 流感疫苗接种对慢性阻塞性肺疾病患者急性加重频率影响回顾性队列研究[J]. 华南预防医学, 2025, 51(9): 1017-1020.
[5] 李燕, 张琳, 安志杰, 等. 23价肺炎球菌多糖疫苗在慢性阻塞性肺疾病患者中的免疫原性和效果[J]. 中国公共卫生, 2021, 37(4): 580-583.
[6] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版)[J]. 中华结核和呼吸杂志, 2021, 44(3): 170-205.
[7] Micheletto C, Aliberti S, Andreoni M, et al.Vaccination strategies in respiratory diseases: Recommendation from AIPO-ITS/ETS, SIMIT, SIP/IRS, and SItI[J]. Respiration, 2025, 104(8): 556-574.
[8] Simon S, Joean O, Welte T, et al.The role of vaccination in COPD: Influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus[J]. Eur Respir Rev, 2023, 32(169): 230034.
[9] 刘聪, 彭雅婷, 李静, 等. 慢性阻塞性肺疾病初诊患者流感和肺炎疫苗接种状况及影响因素:真实世界横断面研究[J]. 中华结核和呼吸杂志, 2022, 45(4): 355-361.
[10] Eiden AL, Hartley L, Garbinsky D, et al.Adult vaccination coverage in the United States: A database analysis and literature review of improvement strategies[J]. Hum Vaccin Immunother, 2024,20(1): 2381283.
[11] 刘娜, 沈嘉, 高金玲, 等. 2023年苏州市太仓市≥60岁老年人肺炎球菌, 乙型肝炎和流感疫苗接种影响因素调查[J]. 中国疫苗和免疫, 2025, 31(2): 148-152.
[12] 王璐瑶, 张秀峰, 王慧虹, 等. 慢性阻塞性肺疾病患者百白破疫苗接种意愿的影响因素分析[J]. 海南医学, 2022, 33(12): 1574-1577.
[13] 朱琳, 高静, 柏丁兮, 等. 中国老年人肺炎球菌疫苗接种意愿影响因素的Meta分析[J]. 中华疾病控制杂志, 2022, 26(1): 91-98.
[14] 徐伟, 王华东, 窦婷婷, 等. 安徽省9个县区35~75岁慢性阻塞性肺疾病患者流感疫苗和肺炎球菌多糖疫苗接种率调查[J]. 中国疫苗和免疫, 2025, 31(2): 138-142.
[15] Li M, Zhang Q, Yue Y, et al.The status and influencing factors of COVID-19 vaccination in patients with COPD[J]. Sci Rep, 2024, 14(1): 16917.
[16] 侯赛, 朱标, 朱梦, 等. 安徽省部分地区医务人员流感疫苗接种意愿及影响因素分析[J]. 实用预防医学, 2025, 32(9): 1032-1035.
[17] 王雯, 张春焕, 张周斌, 等. 广州市老年人23价肺炎球菌多糖疫苗接种意愿及影响因素分析[J]. 中国预防医学杂志, 2024, 25(3): 372-378.
[18] 沈征锴, 田思雨, 王志勇, 等. 南京市老年慢性病患者流感, 肺炎链球菌肺炎, 带状疱疹疾病及疫苗KAP调查[J]. 中国公共卫生, 2024, 40(10): 1261-1265.
[19] 杨倩倩, 李宁, 李瑞, 等. 有免疫接种意愿人群的流感相关知识对流感疫苗接种意愿的影响分析[J]. 中国健康教育, 2024, 40(11): 971-975.
[20] 马豪, 张婷, 彭苏霞, 等. 西南某市未接种流感疫苗老年人群的知信现状与接种意愿的影响因素研究[J]. 现代预防医学, 2024, 51(7): 1290-1294.
[21] Stephens AB, Hofstetter AM, Stockwell MS.Influenza vaccine hesitancy: Scope, influencing factors, and strategic interventions[J]. Pediatr Clin North Am, 2023, 70(2): 227-241.
[22] Nicholls LAB, Gallant AJ, Cogan N, et al.Older adults' vaccine hesitancy: Psychosocial factors associated with influenza, pneumococcal, and shingles vaccine uptake[J]. Vaccine, 2021, 39(26): 3520-3527.
[23] Boesing M, Albrich W, Bridevaux PO, et al.Vaccination in adult patients with chronic lung diseases[J]. Praxis (Bern 1994), 2024, 113(11-12): 297-305.
[24] Guo J, Jiao X, Yuan S, et al.Factors associated with influenza vaccination among urban community-dwelling Chinese elderly: Results from a multicity cross-sectional study[J]. Vaccines (Basel), 2025, 13(11): 1171.
[25] Saiphoklang N, Phadungwatthanachai J.Factors influencing acceptance of influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease[J]. Hum Vaccin Immunother, 2022, 18(6): 2102840.

Uptake of influenza and 23-valent pneumococcal polysaccharide vaccines and associated factors among patients with chronic obstructive pulmonary disease

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 0

[1]	. [J]. South China Journal of Preventive Medicine, 2026, 52(6): 714-718.
[2]	Li Wu, Tan Huiling, Zhuang Chunyan, Liang Fangxin, Chen Wanyi, Yu Jiaxuan, Zeng Ruikun, Liu Feng, Wei Houming. Analysis of the vaccination trends of non-Expanded Program on Immunization vaccines in Longgang District, Shenzhen, from 2015 to 2024 [J]. South China Journal of Preventive Medicine, 2026, 52(5): 512-517.
[3]	Luo Jinjun, Jin Huan, Zhang Zheng, Shen Heng, Lyu Tu, Li Ning, Wang Lei. Surveillance and analysis of adverse events following BCG immunization in Hubei Province, 2017-2023 [J]. South China Journal of Preventive Medicine, 2026, 52(5): 518-522.
[4]	. [J]. South China Journal of Preventive Medicine, 2026, 52(4): 461-464.
[5]	. [J]. South China Journal of Preventive Medicine, 2026, 52(3): 336-339.
[6]	. [J]. South China Journal of Preventive Medicine, 2026, 52(2): 224-228.
[7]	LI xiaoling, YANG Guangshu. Epidemiological characteristics of varicella breakthrough cases in children under 14 years of age in Guangyuan, 2017-2022 [J]. South China Journal of Preventive Medicine, 2025, 51(12): 1305-1309.
[8]	. [J]. South China Journal of Preventive Medicine, 2025, 51(11): 1240-1244.
[9]	. [J]. South China Journal of Preventive Medicine, 2025, 51(10): 1110-1114.
[10]	MA Shuli, YANG Chun, LIU Jiacong, HAO Xiaomeng, SU Lei, CENG Lishi, LI Jiamin, GUO Xuning. Analysis of the effects of age and physical activity duration on populations at high risk for chronic diseases [J]. South China Journal of Preventive Medicine, 2025, 51(9): 973-977.
[11]	. [J]. South China Journal of Preventive Medicine, 2025, 51(9): 991-996.
[12]	. [J]. South China Journal of Preventive Medicine, 2025, 51(9): 997-1000.
[13]	. [J]. South China Journal of Preventive Medicine, 2025, 51(9): 1001-1004.
[14]	. [J]. South China Journal of Preventive Medicine, 2025, 51(9): 1034-1037.
[15]	LU Weicai, LIU Yuqing, DUAN Qintong, HUANG Lirong. Safety of an inactivated enterovirus 71 vaccine among people aged 6 months to 49 years: A phase I clinical trial [J]. South China Journal of Preventive Medicine, 2025, 51(6): 632-637.